Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
5.84
Dollar change
-0.41
Percentage change
-6.56
%
Index- P/E- EPS (ttm)-5.77 Insider Own30.06% Shs Outstand26.45M Perf Week-7.74%
Market Cap151.90M Forward P/E- EPS next Y-2.53 Insider Trans12.88% Shs Float18.19M Perf Month-20.44%
Income-164.57M PEG- EPS next Q-0.78 Inst Own50.60% Short Float9.56% Perf Quarter-16.57%
Sales9.94M P/S15.28 EPS this Y43.20% Inst Trans93.37% Short Ratio8.54 Perf Half Y48.98%
Book/sh0.63 P/B9.27 EPS next Y23.33% ROA-79.76% Short Interest1.74M Perf Year110.83%
Cash/sh5.36 P/C1.09 EPS next 5Y- ROE-227.94% 52W Range2.09 - 8.17 Perf YTD-25.03%
Dividend Est.- P/FCF- EPS past 5Y21.16% ROI-235.96% 52W High-28.52% Beta1.75
Dividend TTM- Quick Ratio3.95 Sales past 5Y169.29% Gross Margin77.33% 52W Low179.40% ATR (14)0.42
Dividend Ex-Date- Current Ratio3.95 EPS Y/Y TTM77.06% Oper. Margin-1540.55% RSI (14)33.83 Volatility5.59% 6.10%
Employees68 Debt/Eq3.73 Sales Y/Y TTM-33.23% Profit Margin-1656.51% Recom1.00 Target Price20.67
Option/ShortYes / Yes LT Debt/Eq3.19 EPS Q/Q-1167.09% Payout- Rel Volume2.14 Prev Close6.25
Sales Surprise-80.65% EPS Surprise-90.56% Sales Q/Q151.19% EarningsMar 27 BMO Avg Volume203.61K Price5.84
SMA20-12.33% SMA50-15.50% SMA20028.45% Trades Volume431,796 Change-6.56%
Date Action Analyst Rating Change Price Target Change
Nov-04-20Upgrade H.C. Wainwright Neutral → Buy $11 → $15
Sep-22-20Initiated Alliance Global Partners Buy $18
Jan-17-20Downgrade Wedbush Outperform → Neutral
Mar-08-19Resumed JMP Securities Mkt Outperform $18
Feb-14-19Resumed Oppenheimer Outperform $13
Nov-05-18Upgrade ROTH Capital Neutral → Buy
Mar-13-18Reiterated Wedbush Outperform $11 → $13
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-27-24 11:53AM
07:30AM
Mar-25-24 07:00AM
Mar-20-24 07:00AM
Feb-27-24 07:00AM
04:00PM Loading…
Jan-31-24 04:00PM
Jan-19-24 10:43AM
Jan-18-24 12:00PM
Jan-17-24 08:50AM
Jan-16-24 12:00PM
09:55AM
Jan-11-24 08:48AM
Jan-08-24 07:00AM
Jan-03-24 11:03PM
Dec-19-23 07:27AM
09:44AM Loading…
Dec-07-23 09:44AM
Dec-06-23 07:00AM
Dec-03-23 04:17PM
Nov-21-23 07:30AM
Nov-15-23 01:08PM
Nov-14-23 07:30AM
Nov-07-23 07:30AM
Oct-02-23 08:45AM
Sep-07-23 04:30PM
Aug-08-23 09:49PM
09:05AM
07:30AM
Aug-04-23 04:30PM
Aug-01-23 07:30AM
Jul-27-23 06:29AM
05:40PM Loading…
Jul-21-23 05:40PM
Jul-05-23 04:30PM
Jun-22-23 08:14PM
Jun-13-23 08:00AM
Jun-08-23 07:30AM
Jun-01-23 04:30PM
May-25-23 05:05PM
08:44AM
May-13-23 10:15AM
May-10-23 10:08PM
08:45AM
07:30AM
May-09-23 07:00AM
May-07-23 08:40PM
May-03-23 07:30AM
May-02-23 07:00AM
Mar-06-23 09:48AM
Mar-04-23 07:08AM
Mar-02-23 10:02PM
09:35AM
07:30AM
Feb-28-23 07:30AM
Feb-23-23 07:30AM
Feb-09-23 04:05PM
Feb-01-23 09:43AM
Jan-26-23 07:00AM
Jan-09-23 07:00AM
Dec-23-22 04:05PM
Dec-16-22 06:47AM
Dec-12-22 07:30AM
Dec-10-22 10:00AM
Dec-05-22 07:00AM
Nov-22-22 07:30AM
Nov-14-22 08:45AM
07:30AM
Nov-07-22 07:30AM
Nov-04-22 04:30PM
Nov-03-22 09:01AM
Oct-05-22 04:01PM
Sep-23-22 12:00PM
Sep-16-22 04:05PM
Sep-15-22 04:13PM
Sep-14-22 01:26PM
Sep-13-22 04:01PM
Sep-07-22 07:30AM
Sep-02-22 04:01PM
Aug-09-22 08:45AM
08:30AM
07:30AM
Aug-04-22 04:01PM
Aug-03-22 04:01PM
Aug-02-22 07:30AM
Jul-28-22 10:33AM
Jul-13-22 12:00PM
Jul-06-22 11:31AM
Jul-05-22 04:48PM
07:59AM
07:00AM
Jul-01-22 04:01PM
Jun-20-22 07:43AM
Jun-08-22 07:30AM
Jun-03-22 04:01PM
May-16-22 08:45AM
07:30AM
May-13-22 08:13AM
May-11-22 08:59AM
May-09-22 07:30AM
Apr-29-22 04:01PM
Apr-20-22 11:01AM
Apr-11-22 09:21AM
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AKKARAJU SRINIVASDirectorDec 21 '23Buy4.42904,9773,999,9981,786,427Dec 26 05:24 PM
Roth DavidChief Medical OfficerDec 12 '23Sale4.956,28731,1210Dec 14 04:24 PM
Roth DavidChief Medical OfficerDec 06 '23Sale3.956,28724,8346,287Dec 08 04:23 PM
Roth DavidChief Medical OfficerJul 31 '23Sale3.957,34829,0250Aug 02 04:21 PM
Olson Eric RChief Scientific OfficerJul 17 '23Sale3.506892,4126,661Jul 18 08:27 PM